ClinicalTrials.gg
CompletedNCT03385551Updated Feb 11, 2021

Study to Evaluate Estradiol Vaginal Tablets vs Promestriene Vaginal Cream

An observational study in Vulvovaginal Atrophy, sponsored by Instituto Palacios. Completed at 2 sites in 2 countries. Open to female participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2021-02-11.

Sponsored by Instituto Palacios · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
45 Years and older
Sex
Female
01

Study summary

This is a study to evaluate the acceptability, efficacy and preferences of 10 of estradiol vaginal tablets vs promestriene vaginal cream

Read the detailed description

This is an observational, prospective, open-label, parallel-group study to evaluate the acceptability, efficacy, and preferences of postmenopausal women older than 45 between 10 micrograms of estradiol vaginal tablets vs promestriene vaginal cream

02

Conditions studied

  • Vulvovaginal Atrophy

Keywords

  • Vulvovaginal Atrophy
03

In context

Lead sponsor

Instituto Palacios is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

120 postmenopausal women aged 45 years or older, with one or more moderate to severe symptoms of vulvovaginal atrophy (dryness, dyspareunia, soreness or irritation)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

women aged 45 years or older. Women will be considered postmenopausal with more than 12 months since last menstrual period

  • Women who have been prescribed vaginal estradiol tablets or vaginal promestriene cream· Women who have read and signed the Form
  • Women with an intact uterus
  • One or more vaginal symptoms (dryness, soreness, irritation, dyspareunia) rated as moderate to severe. Symptoms are moderate if the patient needs a treatment and feels discomfort. Symptoms are severe if the patient needs a treatment, and feels such a degree of discomfort that this could severely impact the subject's daily activities
  • In case of doubt, blood estradiol concentration will be determined, and the subject will only be enrolled if the levels are equal to 30pg./ml. or less.

Exclusion criteria

Exclusion Criteria:

  • Women who had a known or suspected history of breast carcinoma

    • Estrogen dependent neoplasia. Women with a known, past or suscpected Estrogen-dependent malignant tumours such as endormetrial or ovarian cancer
    • Positive or suspicious mammogram results
    • Any systemic malignant disease
    • Hormone therapy treatment (sex hormones or vaginal treatments or ) in the last three months Women who had abnormal vaginal bleeding or uterine bleeding of unknown cause
    • Vaginal infection requiring treatment
    • Previous or current venous thromboembolism (deep venous thrombosis, pulmonary embolism) Untreated endometrial hyperplasia Known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency) Active or previous arterial thromboembolic disease (e.g. angina, myocardial infarction) Acute liver disease, or history of liver disease as long as liver function tests have failed to return to normal Known to the active substances or to any of the Porphyria
    • Any serious disease or chronic condition that could interfere with study compliance
    • History of thrombolytic disorders
    • Use of vaginal (DIU, vaginal ring...)
    • Participation in another clinical trial in the last three months.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (actual)
Patient registry
No

Groups and cohorts

  • ARM 1

    Patients who have been prescribed by the physician within the standard clinical practice 10 micrograms of estradiol vaginal tablets. One tablet intravaginally once daily for two weeks. Thereafter one tablet twice per week with at least a 3-days interval between treatments

    Drug: Estradiol

  • ARM 2

    Patients who have been prescribed by the physician within the standard clinical practice promestriene 10mg./g vaginal cream. 1 gr. one application once daily intravaginally for two weeks. Thereafter one application twice per week with at least a 3-days interval between treatments

Interventions

  • Estradiol or Promestriene depending on the arm

    Also known as: Promestriene

06

What researchers measure

Primary outcomes

  1. Vulvovaginal Symptoms

    Dispareunya, dryness, itching nd burning

    Time frame: Change from Baseline, at week 4 and at week 12

07

Study locations

2 sites
  • IRCCS "S Matteo Foundation"
    Pavia, Italy
  • Instituto Palacios
    Madrid, 28009, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Jun 2020, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2017
First posted
Dec 28, 2017
StartActual
Dec 9, 2019
Primary completionActual
Jun 30, 2020
CompletionActual
Sep 30, 2020
Last update
Feb 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03385551
Lead sponsor
Instituto Palacios
Responsible party
Sponsor
First posted
Dec 28, 2017
Start date
Dec 9, 2019
Primary completion
Jun 30, 2020
Completion
Sep 30, 2020
Last update
Feb 11, 2021

Study contacts

Santiago Palacios, MD
principal investigator · Instituto Palacios

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion